Yes would love a green close

Yes and more once in nasdaq

Still 2.04 ask pre market

We are looking at our next steps with regards to commercialization of our Strontium89 drug coupled with our desire to list on the NASDAQ as quickly as possible. Making this the right time to work on our balance sheet and eliminate as much debt as possible. We worked with a trusted partner and converted out about $4,000,000 of debt into equity. This also allowed to fund our current operations and pipeline of key assets.”

In addition to the work the Company has been doing in its core markets, QBIO has also announced a key financing and restructuring of debt. Corin stated: “Q BioMed Inc. has been around roughly five years and I am thrilled with the progress that we have made over those years. We are now in a revenue generating state. 

Denis Corin, CEO of Q BioMed Inc., called back in to SmallCapVoice.com for a follow up interview to discuss the recent news and events for the Company. Early in the coronavirus saga, that would evolve into a global health pandemic, QBIO made a major announcement about the work being done along with its research partner Mannin Research Inc. The combined efforts of the two companies was to develop a potential adjunct treatment for various infectious diseases like the coronavirus. Recent news highlighted the urgency for the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. Corin gives an update as well as an overall overview of QBIO’s work in this area.

Yes I'll keep an eye on it daily

To see higher pps i meant

Technically and fundamentally ready to go

Yes

Yup with covid and it's other milestones

If goes down will start accumulating some

Well I'll keep an eye on it today

I agree, need to be on the NAS

Nice

Yes good sign that it's holding on low volume

Still lot of chatters out there good sign

Yes on strong volume

$GILD Data on Gilead drug raises hopes in pandemic fight, $QBIO $QBIO Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics $IBB #Biotech

$GILD Data on Gilead drug raises hopes in pandemic fight, $QBIO $QBIO Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics $IBB #Biotech

$PFE $BNTX $QBIO $GILD Pfizer, BioNtech, Q biomed, Gilead Sciences and other companies are racing to develop a vaccine, since there are currently no approved treatments and only mixed results of medicines under study against the virus.

Let's see what's up over the next few weeks

Yes huge $ potential whoever wins the race will see it's sales blow up within weeks

$PFE $BNTX $QBIO $GILD Pfizer, BioNtech, Q biomed, Gilead Sciences and other companies are racing to develop a vaccine, since there are currently no approved treatments and only mixed results of medicines under study against the virus.

$PFE $BNTX $QBIO $GILD Pfizer, BioNtech, Q biomed, Gilead Sciences and other companies are racing to develop a vaccine, since there are currently no approved treatments and only mixed results of medicines under study against the virus.

Biotech sector will blow up within the next few weeks

Pfizer has dedicated about $500 million to its coronavirus drug and vaccine research efforts and another $150 million to increasing production capacity, the Journal noted.

could become available within a month if the trial starts as expected.

If the initial clinical trials are successful, Pfizer could provide the vaccine on an "emergency basis" to the public, and receive approval for widespread distribution by the year's end, the Journal reported.

"You can imagine the demand for something like that will be extremely, extremely high," Bourla said.

Pfizer is developing an mRNA vaccine candidate for COVID-19 in partnership with Germany's BionNTech SE (NASDAQ: BNTX).

Pfizer Inc. (NYSE: PFE) chief executive officer Albert Bourla on Tuesday said the clinical trials for its novel coronavirus (COVID-19) vaccine are expected to start next week in the United States, pending approval from health regulators.

Biotechs on fire soon

Pfizer Says Coronavirus Vaccine Could Be Available By Fall, US Clinical Trials To Begin Next Week

Let's close green today

Yes definitely

Def

Almost 100% gain away from recent high

Will go up very fast like last time

All good down here HOLD

$QBIO Cyclica is a Toronto, Canada based biotechnology company that is decentralizing the discovery of new medicines with its integrated structure-based and AI-augmented drug discovery platform, Ligand Design and Ligand Express. Taken together Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. Cyclica's differentiated platform opens new opportunities for drug discovery, including multi-targeted and multi-objective drug design, lead optimization, ADMET-property prediction, target deconvolution, and drug repurposing for a wide range of indications.

$QBIO Mannin's core R&D program is based on the Angiopoeitin-Tie2 Mechanism of Action. Mannin's small molecules and its biologic therapeutic target the endothelium of the patient, stabilizing endothelial barrier integrity by activating Tie2, which in turn reduces lung endothelial vascular leakage, inflammation and cell death that occurs during severe viral infection. This is a novel and promising therapeutic strategy as its mechanism of action is independent of viral replication, but instead focuses on endothelium of the host as the critical target for treatment intervention.

$QBIO Mannin is developing therapeutics with mechanism of action involving the Angiopoietin-Tie2 signaling pathway, which is a major regulator of vascular development, vessel remodeling, postnatal angiogenesis, and vessel permeability. Therefore, targeting this pathway has very broad therapeutic applications.